My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Crinetics Pharmaceuticals, Inc. - Common Stock (NQ:CRNX)

50.49 +1.18 (+2.39%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 12, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Crinetics Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

February 14, 2024

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 12, 2024

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 23, 2024

Via Benzinga

Analyst Scoreboard: 4 Ratings For Crinetics Pharmaceuticals ↗

December 19, 2023

Via Benzinga

8 Analysts Have This to Say About Crinetics Pharmaceuticals ↗

November 20, 2023

Via Benzinga

11 Analysts Have This to Say About Crinetics Pharmaceuticals ↗

October 24, 2023

Via Benzinga

Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 10, 2024

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

January 03, 2024

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 28, 2023

Via Benzinga

Why Crinetics Pharmaceuticals Stock Soared This Week ↗

September 15, 2023

A positive late-stage trial readout fueled a major rally in the drugmaker's shares.

Via The Motley Fool

Endocrine Diseases-Focused Crinetics Pharmaceuticals Highlights Favorable Initial Findings From Mid-Stage Study ↗

December 19, 2023

Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) released initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) study of paltusotine, an oral, once-daily investigational compound...

Via Benzinga

Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome

December 18, 2023

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 11, 2023

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences

November 20, 2023

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 10, 2023

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 07, 2023

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment

October 11, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GNLX),(NASDAQ:CRNX),(NYSE:PFE),(NASDAQ:SGEN) EQNX::TICKER_END

Via FinancialNewsMedia

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 10, 2023

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

October 09, 2023

Via Benzinga

7 Speculative Stocks Set to Explode Higher ↗

October 03, 2023

On the search for high-risk, high-reward opportunities? Consider taking a look at these seven speculative stocks.

Via InvestorPlace

Top 4 Health Care Stocks That Should Keep You Up At Night ↗

September 21, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023

September 20, 2023

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Up 83% in 5 Days, Is Crinetics Pharmaceuticals a Buy? ↗

September 19, 2023

Despite good results in phase 3 trials, there are barriers to its drug candidate's success.

Via The Motley Fool

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

September 12, 2023

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

What's Going On With Crinetics Pharmaceuticals Stock? ↗

September 12, 2023

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) shares are trading higher Tuesday.

Via Benzinga

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

September 11, 2023

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Nasdaq Rises Over 1%; Hostess Brands Shares Spike Higher ↗

September 11, 2023

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 1% on Monday. The Dow traded up 0.29% to 34,676.52 while the NASDAQ rose 1.16% to 13,920.60. The S&P...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 11, 2023

Via Benzinga

Why Avantax Shares Are Trading Higher By Over 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

September 11, 2023

Gainers Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study...

Via Benzinga

Why Shares of Crinetics Pharmaceuticals Are Jumping Monday ↗

September 11, 2023

The biotech company reported positive phase 3 trial results.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.